The effect of resveratrol on advanced glycation end products in diabetes mellitus: a systematic review

Arch Physiol Biochem. 2022 Feb;128(1):253-260. doi: 10.1080/13813455.2019.1673434. Epub 2020 Mar 3.

Abstract

Advanced glycation end products (AGEs) lead to chronic oxidative stress and inflammation, which in turn augment diabetes complications. Resveratrol plays a potential role in relation to diabetes due to improving of hyperglycemia, oxidative stress, and inflammation. The aim of this review was to evaluate the scientific literature to identify the impacts of resveratrol on the accumulation of AGEs. The literature was searched in the online databases, viz. PubMed, SCOPUS, Embase, ProQuest, and Google Scholar until May 2019. From a total of 338 retrieved articles, 10 papers were eligible for the present analysis. Except one clinical trial, all studies were conducted on animals. All the included studies, except one, showed inhibitory effects of resveratrol on the accumulation of AGE or receptor for AGEs. The findings indicate that resveratrol is a potential protective agent against the accumulation of AGEs. There is, however, the need for future studies to investigate this effect on human.

Keywords: Resveratrol; advanced glycation end products; diabetes.

Publication types

  • Systematic Review

MeSH terms

  • Animals
  • Antioxidants / therapeutic use
  • Diabetes Mellitus* / drug therapy
  • Glycation End Products, Advanced* / metabolism
  • Humans
  • Oxidative Stress
  • Resveratrol / pharmacology
  • Resveratrol / therapeutic use

Substances

  • Antioxidants
  • Glycation End Products, Advanced
  • Resveratrol